These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 28381577)

  • 1. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
    Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
    Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
    J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of resistance to favipiravir in influenza.
    Goldhill DH; Te Velthuis AJW; Fletcher RA; Langat P; Zambon M; Lackenby A; Barclay WS
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11613-11618. PubMed ID: 30352857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.
    Komeno T; Furuta Y; Nakajima N; Tani H; Morinaga Y
    Antiviral Res; 2022 Sep; 205():105387. PubMed ID: 35931138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virus.
    Wada Y; Orba Y; Sasaki M; Kobayashi S; Carr MJ; Nobori H; Sato A; Hall WW; Sawa H
    Virology; 2017 May; 505():102-112. PubMed ID: 28236746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
    Furuta Y; Komeno T; Nakamura T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):449-463. PubMed ID: 28769016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir.
    Daikoku T; Mizuguchi M; Obita T; Yokoyama T; Yoshida Y; Takemoto M; Shiraki K
    J Microbiol Immunol Infect; 2018 Oct; 51(5):581-586. PubMed ID: 28709841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
    Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters.
    Jochmans D; van Nieuwkoop S; Smits SL; Neyts J; Fouchier RA; van den Hoogen BG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4620-9. PubMed ID: 27185803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype.
    Naito T; Shirai K; Mori K; Muratsu H; Ushirogawa H; Ohniwa RL; Hanada K; Saito M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagen resistance and mutation restriction of St. Louis encephalitis virus.
    Griesemer SB; Kramer LD; Van Slyke GA; Pata JD; Gohara DW; Cameron CE; Ciota AT
    J Gen Virol; 2017 Feb; 98(2):201-211. PubMed ID: 28284278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses.
    Tokunaga T; Yamamoto Y; Sakai M; Tomonaga K; Honda T
    Antiviral Res; 2017 Jul; 143():237-245. PubMed ID: 28465146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
    Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
    Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.
    Delang L; Abdelnabi R; Neyts J
    Antiviral Res; 2018 May; 153():85-94. PubMed ID: 29524445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.
    Escribano-Romero E; Jiménez de Oya N; Domingo E; Saiz JC
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.
    Zhu W; Zhang Z; He S; Wong G; Banadyga L; Qiu X
    Antiviral Res; 2018 Mar; 151():39-49. PubMed ID: 29369776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Polymerase-Helicase Complexes Regulate Replication Fidelity To Overcome Intracellular Nucleotide Depletion.
    Stapleford KA; Rozen-Gagnon K; Das PK; Saul S; Poirier EZ; Blanc H; Vidalain PO; Merits A; Vignuzzi M
    J Virol; 2015 Nov; 89(22):11233-44. PubMed ID: 26311883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMO Modification Stabilizes Enterovirus 71 Polymerase 3D To Facilitate Viral Replication.
    Liu Y; Zheng Z; Shu B; Meng J; Zhang Y; Zheng C; Ke X; Gong P; Hu Q; Wang H
    J Virol; 2016 Dec; 90(23):10472-10485. PubMed ID: 27630238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection.
    Abdelnabi R; Jochmans D; Verbeken E; Neyts J; Delang L
    Antiviral Res; 2018 Jan; 149():113-117. PubMed ID: 28958920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
    Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
    Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.